Wordt geladen...
Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner
Palbociclib, a CDK4/6 inhibitor, has recently been approved for hormone receptor‐positive breast cancer patients. The effects of palbociclib as a treatment for other malignancies, including hepatocellular carcinoma (HCC), are of great clinical interest and are under active investigation. Here, we re...
Bewaard in:
| Gepubliceerd in: | Mol Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5537702/ https://ncbi.nlm.nih.gov/pubmed/28453226 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12072 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|